Fig. 5From: Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysisPersistency chart (proportional hazards model) for octreotide vs lanreotide, all patients (n = 1308). Survival indicates probability of patients continuing treatment. Hazard ratio (risk of discontinuing treatment) for octreotide vs lanreotide: 1.164; p = 0.155Back to article page